Elon Musk backed artificial intelligence (AI) to deliver one of medicine’s biggest breakthroughs after Anthropic CEO Dario Amodei argued that AI companies must prove their value with tangible results such as curing cancer rather than relying on optimistic marketing.
Amodei Says AI Must Deliver Results
"AI will do it," Musk wrote on X in response to Russell Brand highlighting Amodei’s remarks. Amodei said public skepticism reflects a broader "crisis of trust" and added, "The thing that will work is actually curing cancer." He argued AI companies have not yet delivered on their biggest promises.
AI will do it
— Elon Musk (@elonmusk) August 18, 2026
Amodei has long made an aggressive case for AI in biology. In his "Machines of Loving Grace" essay, he argued powerful AI could compress roughly 50 to 100 years of biological progress into five to 10 years by accelerating experimental design and discovery, while acknowledging constraints from physical experiments, data quality and clinical trials. Earlier coverage highlighted his prediction that AI could help "cure most human disease" within roughly five to 10 years.
Musk has voiced similarly sweeping expectations. In June, he argued advances in synthetic RNA could make medicine increasingly programmable and potentially "cure almost anything."
Researchers Put AI Deeper Into Oncology
AI is already moving deeper into oncology research. The National Cancer Institute says researchers use AI to accelerate screening, model drug responses, predict patient outcomes and help design therapies. The FDA and European Medicines Agency also issued joint principles this year for responsible AI use across drug development.
At Lawrence Berkeley National Laboratory, researchers at the beginning of the year, used AI to generate 2,600 tumor-targeting protein designs in 30 hours, identifying promising candidates in under two weeks rather than through years of trial and error.
AI Speeds Early Cancer Target Discovery
Penn Medicine researchers in June separately built a human-in-the-loop AI framework for identifying CAR T-cell targets. It prioritized GPNMB, and a therapy built around that target showed tumor-killing activity in mouse models of melanoma, leukemia and colorectal cancer. The researchers reduced a discovery process that can take months or years to a few weeks.
Those advances remain preclinical, and cancer comprises many biologically distinct diseases rather than one condition. Amodei’s challenge is therefore less a promise of an imminent universal cure than a demand that AI companies replace hype with measurable progress.
Photo courtesy: Shutterstock
